InspireMD (NSPR)
Develops CGuard mesh-covered carotid stents for stroke prevention.
Something off on this page? Send us feedback.
Sells the CGuard carotid-stent platform, built on MicroNet mesh technology, for carotid disease and stroke prevention. CGuard EPS is sold internationally through distributors, while CGuard Prime is commercialized directly in the United States.
Builds the CGuard carotid-stent platform around proprietary MicroNet mesh technology for carotid disease and stroke prevention. CGuard EPS and CGuard Prime are manufactured in Tel Aviv; EPS is sold internationally through distributors, while Prime is sold directly in the United States. International sales remain distributor-led, in contrast with the direct U.S. rollout.
U.S. commercialization of CGuard Prime followed FDA premarket approval and is supported by direct-sales capacity developed from Miami. The business is concentrated on this platform rather than a broad device portfolio and depends on regulatory clearances, U.S. commercial execution, and access to capital.
Company facts
Categories
Target rangeAs of Sep 2, 2026
Latest analyst notes
| Date | Firm | Action | Rating | Prior target | Target |
|---|---|---|---|---|---|
| May 5, 2026 | Piper Sandler | Reiterate | Overweight | $4.50 | $3 |
| May 4, 2026 | Lake Street | Target | $5 | $4 | |
| Feb 24, 2026 | Loop Capital Markets | Target | $5 | ||
| Feb 2, 2026 | Maxim Group | Target | $6 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $30.4M · Total debt $2.0M · Total assets $44.6M · Shareholders' equity $31.5M
- Revenue
- $1.8M
- Operating income
- −$14.4M
- Net income
- −$14.3M
No dividends on record.
| Institutions34 holders · as of Mar 31, 2026 | 49.05% | 22.80M shares | |
| Insiders13 holders · as of May 29, 2026 | 26.96% | 12.53M shares | |
| Strategic holders2 holders · as of Feb 2, 2026 | 6.83% | 3.17M shares | |
| Otherremainder | 17.16% | 7.98M shares |
46.49M company shares as of Sep 3, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Rosalind Advisors, Inc.Institution | 8.40% | 3.91M | 13Fas of Mar 31, 2026 |
Michael A. Lawless1Insiderofficer: Chief Financial Officer | 8.26% | 3.61M | 13Dfiled Jan 16, 2026 ↗ |
Nantahala Capital Management, LLCInstitution | 7.26% | 3.38M | 13Fas of Mar 31, 2026 |
Abrdn PLCInstitution | 6.83% | 3.17M | 13Fas of Mar 31, 2026 |
Aberdeen Group plcStrategic | 6.83% | 3.17M | 13Gfiled Feb 2, 2026 ↗ |
| See all 25 → | |||
- Michael A. Lawless's transaction reports restate only vehicles that traded; the 2025 ownership statement (3.61M) plus the 226.7K net shares acquired since is used instead.
13F — a manager's quarterly holdings · 13D/13G — an ownership statement filed at 5% or more
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| May 27, 2026 | Paul Stuka | director | +20,000 | $0.8750 |
| May 19, 2026 | Shane Thomas Gleason | officer: Chief Commercial Officer | −22,778 | $1.01 |
| Feb 2, 2026 | Shane Thomas Gleason | officer: Chief Commercial Officer | −4,941 | $1.60 |
| May 30, 2025 | Shane Thomas Gleason | officer: Chief Commercial Officer | −7,186 | $2.51 |
| May 29, 2025 | Shane Thomas Gleason | officer: Chief Commercial Officer | −3,760 | $2.51 |
- Boston Scientific
TCAR platform competition in carotid stroke prevention
- Abbott
Carotid stents and embolic protection systems
- Medtronic
Integrated carotid stenting and embolic protection
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| InspireMD | $0.8694 | −4.30% | $39.4M | — | — | 3.6 | −0.4% |
| Boston Scientific | $48.42 | +0.09% | $71.90B | 19.7 | 14.6 | 3.4 | +7.5% |
| Abbott | $110.50 | +0.04% | $191.19B | 35.5 | 19.0 | 4.1 | +13.0% |
| Medtronic | $92.40 | +0.22% | $118.00B | 22.7 | 15.3 | 3.1 | +13.7% |
| Median | 22.7 | 15.3 | 3.4 | +13.0% |